Takeda's $6B Acquired TYK2 Inhibitor TAK-279 Advances into Phase III Clinical Trial for Moderate-to-Severe Plaque Psoriasis

On October 18, the clinicaltrials.gov website showed that Takeda plans to launch a Phase III clinical trial (NCT06088043) on November 20 to evaluate the efficacy and safety of the highly selective oral TYK2 inhibitor TAK-279 compared with placebo or apremilast in patients with moderate to severe plaque psoriasis.

TAK-279 is an oral selective tyrosine kinase 2 (TYK2) inhibitor that Takeda acquired through its $6 billion purchase of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics, at the end of last year. This product is a potential competitor to Bristol-Myers Squibb's first-in-class TYK2 inhibitor, deucravacitinib (Sotyktu).

This study plans to recruit approximately 600 patients, who will be randomly assigned in a 3:1:1 ratio to receive 52 weeks of treatment with TAK-279, placebo, or apremilast. The main study is expected to be completed by August 2025.

In September this year, Takeda announced that the Phase IIb study of TAK-279 for the treatment of active psoriatic arthritis met its primary endpoint. The results showed that, compared with the placebo group, a higher proportion of patients receiving once-daily TAK-279 treatment had at least a 20% improvement in signs and symptoms of the disease at week 12.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message or send a notification to the WeChat Official Account backend, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Highlights

Online Live Streaming & Offline Salon